+86-21-58356573
LANGUAGE

Company news

ImmuneOnco secures 5 million RMB in the second round of pre-A round fund-raising from Shanghai Zhangjiang Science & Technology Venture Capital Co., Ltd (ZJSTVC).

2016/3/1 0:00:00Click:757

   On March 1, 2016, ImmuneOnco Biopharma Co., Ltd, an early-stage immunotherapy company dedicated to development and commercialization of novel cancer immunotherapy products, today announced closing of second round fund-raising in pre-A round as of the amount of 5 million RMB from Shanghai Zhangjiang Science & Technology Venture Capital Co., Ltd (ZJSTVC). “We are honoured to have ZJSTVC to join us. ZJSTVC is a well known state-run investment company which has achieved tremendous credit in investment of great health area. We believe with the support from ZJSTVC, we will advance our projects to the next level of development faster than ever”, commented Dr. Wenzhi Tian, Founder and Chairman of ImmuneOnco.

“As an oversea returnee, Dr. Tian has had great achievements in innovative drug development over the past few years, as best exampled by IND filing to CFDA”, said Ms. Weiwei Chen, Chairman and CEO of ZJSTVC. “We believe Dr. Tian has the capability to build a great team for his company and to develop more innovative drugs with his expertise”, further commented Ms. Weiwei Chen.